Immunotherapy Biomarkers

Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer
Myrto K Moutafi, Magdalena Molero, Sandra Martinez Morilla, Javier Baena, Ioannis A Vathiotis, Niki Gavrielatou, Laura Castro-Labrador, Gorka Ruiz de Garibay, Vera Adradas, Daniel Orive, Karmele Valencia, Alfonso Calvo, Luis M Montuenga, S Ponce Aix, Kurt A Schalper, Roy S Herbst, Luis Paz-Ares, David L Rimm, Jon Zugazagoitia

Journal for ImmunoTherapy of Cancer Aug 2022, 10 (8) e004757; DOI: 10.1136/jitc-2022-004757
Single-cell analysis reveals clonally expanded tumor-associated CD57⁺ CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade
Michael Fehlings, Leesun Kim, Xiangnan Guan, Kobe Yuen, Alireza Tafazzol, Shomyseh Sanjabi, Oliver A Zill, Deepali Rishipathak, Andrew Wallace, Alessandra Nardin, Siming Ma, Ana Milojkovic, Evan W Newell, Sanjeev Mariathasan, Mahesh Yadav

Journal for ImmunoTherapy of Cancer Aug 2022, 10 (8) e004759; DOI: 10.1136/jitc-2022-004759
High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC
Joan Frigola, Caterina Carbonell, Patricia Iranzo, Nuria Pardo, Ana Callejo, Susana Cedres, Alex Martinez-Marti, Alejandro Navarro, Mireia Soleda, Jose Jimenez, Javier Hernandez-Losa, Ana Vivancos, Enriqueta Felip, Ramon Amat

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004197; DOI: 10.1136/jitc-2021-004197
CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
Niklas Klümper, Damian J Ralser, Romina Zarbl, Katrin Schlack, Andres Jan Schrader, Marc Rehlinghaus, Michèle J Hoffmann, Günter Niegisch, Annemarie Uhlig, Lutz Trojan, Julie Steinestel, Konrad Steinestel, Ralph M Wirtz, Danijel Sikic, Markus Eckstein, Glen Kristiansen, Marieta Toma, Michael Hölzel, Manuel Ritter, Sebastian Strieth, Jörg Ellinger, Dimo Dietrich

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002949; DOI: 10.1136/jitc-2021-002949
Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer
Miok Kim, Yong Ki Min, Jinho Jang, Hyejin Park, Semin Lee, Chang Hoon Lee

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002503; DOI: 10.1136/jitc-2021-002503
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma
Riyue Bao, Stefani Spranger, Kyle Hernandez, Yuanyuan Zha, Peter Pytel, Jason J Luke, Thomas F Gajewski, Samuel L Volchenboum, Susan L Cohn, Ami V Desai

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002417; DOI: 10.1136/jitc-2021-002417
DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma
Katharina Filipski, Michael Scherer, Kim N. Zeiner, Andreas Bucher, Johannes Kleemann, Philipp Jurmeister, Tabea I. Hartung, Markus Meissner, Karl H. Plate, Tim R. Fenton, Jörn Walter, Sascha Tierling, Bastian Schilling, Pia S. Zeiner, Patrick N. Harter

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002226; DOI: 10.1136/jitc-2020-002226
Predictive value of 3′-deoxy-3′-¹⁸F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer
Masayuki Sato, Yukihiro Umeda, Tetsuya Tsujikawa, Tetsuya Mori, Miwa Morikawa, Masaki Anzai, Yuko Waseda, Maiko Kadowaki, Yasushi Kiyono, Hidehiko Okazawa, Tamotsu Ishizuka

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e003079; DOI: 10.1136/jitc-2021-003079
ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer
Zongren Wang, Xueling Zhang, Wuguo Li, Qiao Su, Zhaoyang Huang, Xinyao Zhang, Haiqi Chen, Chengqiang Mo, Bin Huang, Wei Ou, Junxing Chen, Guangyin Zhao, Lingwu Chen, Lan Shao

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e001758; DOI: 10.1136/jitc-2020-001758
First-in-human DR5 PET reveals insufficient DR5 expression in patients with gastrointestinal cancer
Shujing Wang, Hua Zhu, Yingjie Li, Jin Ding, Feng Wang, Lixin Ding, Xinyu Wang, Jun Zhao, Yan Zhang, Yunfeng Yao, Tong Zhou, Nan Li, Aiwen Wu, Zhi Yang

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002926; DOI: 10.1136/jitc-2021-002926

Main menu

Immunotherapy Biomarkers

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immunotherapy Biomarkers

Pages